Thus, there was a discrepancy in the time between tumor sampling and anti-PD1 therapy, which means that there was time gap between genomic and/or transcriptomic status and ICIs treatment response status Actually, the population of this study included either first-line therapy (n = 8) or more than second-line treatments that failed withTyrosine Kinase inhibitors (TKIs, n = 52). The gene discussed is PDCD1; the disease is neoplasm.